meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
PD-L1 < 5%
PD-L1 > 5%
stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
hypothyroidism (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE grade 3-5 (PE)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Arthralgia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
deaths (OS)
mML - L1 - all population
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - all population
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab
1
certainty unassessable
-48%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open